Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220839484> ?p ?o ?g. }
- W4220839484 abstract "Half the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. 131I-mIBG is the most widely used form in current use, but is not universally effective. Clinical trials of 177Lutetium DOTATATE have so far had disappointing results, possibly because the administered activity was too low, and the courses were spread over too long a period of time, for a rapidly proliferating tumor. We have devised an alternative administration schedule to overcome these limitations. This involves two high-activity administrations of single agent 177Lu-DOTATATE given 2 weeks apart, prescribed as a personalized whole body radiation absorbed dose, rather than a fixed administered activity. A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma - LuDO-N (EudraCT No: 2020-004445-36, ClinicalTrials.gov Identifier: NCT04903899) evaluates this new dosing schedule.The LuDO-N trial is a phase II, open label, multi-center, single arm, two stage design clinical trial. Children aged 18 months to 18 years are eligible. The trial is conducted by the Nordic Society for Pediatric Hematology and Oncology (NOPHO) and it has been endorsed by SIOPEN (https://www.siopen.net). The Karolinska University Hospital, is the sponsor of the LuDO-N trial, which is conducted in collaboration with Advanced Accelerator Applications, a Novartis company. All Scandinavian countries, Lithuania and the Netherlands participate in the trial and the UK has voiced an interest in joining in 2022.The pediatric use of the Investigational Medicinal Product (IMP) 177Lu-DOTATATE, as well as non-IMPs SomaKit TOC® (68Ga-DOTATOC) and LysaKare® amino acid solution for renal protection, have been approved for pediatric use, within the LuDO-N Trial by the European Medicines Agency (EMA). The trial is currently recruiting. Recruitment is estimated to be finalized within 3-5 years.In this paper we present the protocol of the LuDO-N Trial. The rationale and design of the trial are discussed in relation to other ongoing, or planned trials with similar objectives. Further, we discuss the rapid development of targeted radiopharmaceutical therapy and the future perspectives for developing novel therapies for high-risk neuroblastoma and other pediatric solid tumors." @default.
- W4220839484 created "2022-04-03" @default.
- W4220839484 creator A5000208648 @default.
- W4220839484 creator A5002282668 @default.
- W4220839484 creator A5006381517 @default.
- W4220839484 creator A5019494622 @default.
- W4220839484 creator A5021655364 @default.
- W4220839484 creator A5022827045 @default.
- W4220839484 creator A5032323430 @default.
- W4220839484 creator A5034848722 @default.
- W4220839484 creator A5045906857 @default.
- W4220839484 creator A5051825864 @default.
- W4220839484 creator A5057281435 @default.
- W4220839484 creator A5064431563 @default.
- W4220839484 creator A5064732539 @default.
- W4220839484 creator A5071719710 @default.
- W4220839484 creator A5077267547 @default.
- W4220839484 creator A5078378771 @default.
- W4220839484 creator A5078789108 @default.
- W4220839484 creator A5085425383 @default.
- W4220839484 date "2022-03-10" @default.
- W4220839484 modified "2023-10-18" @default.
- W4220839484 title "A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N" @default.
- W4220839484 cites W1552818660 @default.
- W4220839484 cites W1605581961 @default.
- W4220839484 cites W1707785540 @default.
- W4220839484 cites W1979276234 @default.
- W4220839484 cites W1994118792 @default.
- W4220839484 cites W1994940008 @default.
- W4220839484 cites W2005674134 @default.
- W4220839484 cites W2016440379 @default.
- W4220839484 cites W2019607817 @default.
- W4220839484 cites W2027362030 @default.
- W4220839484 cites W2028261457 @default.
- W4220839484 cites W2046209641 @default.
- W4220839484 cites W2056762938 @default.
- W4220839484 cites W2058780072 @default.
- W4220839484 cites W2062279034 @default.
- W4220839484 cites W2096398040 @default.
- W4220839484 cites W2098908781 @default.
- W4220839484 cites W2124325993 @default.
- W4220839484 cites W2127775057 @default.
- W4220839484 cites W2134257528 @default.
- W4220839484 cites W2143283097 @default.
- W4220839484 cites W2399406017 @default.
- W4220839484 cites W2400681987 @default.
- W4220839484 cites W2414714916 @default.
- W4220839484 cites W2512768762 @default.
- W4220839484 cites W2553507030 @default.
- W4220839484 cites W2573369749 @default.
- W4220839484 cites W2592061165 @default.
- W4220839484 cites W2605488317 @default.
- W4220839484 cites W2607151521 @default.
- W4220839484 cites W273902486 @default.
- W4220839484 cites W2766322324 @default.
- W4220839484 cites W2775209071 @default.
- W4220839484 cites W2789923927 @default.
- W4220839484 cites W2897613501 @default.
- W4220839484 cites W2902519362 @default.
- W4220839484 cites W2916287599 @default.
- W4220839484 cites W2984670499 @default.
- W4220839484 cites W3011732986 @default.
- W4220839484 cites W3041203464 @default.
- W4220839484 cites W3045665740 @default.
- W4220839484 cites W3049142003 @default.
- W4220839484 cites W3093222707 @default.
- W4220839484 cites W3110064522 @default.
- W4220839484 cites W3164753345 @default.
- W4220839484 cites W3180671804 @default.
- W4220839484 cites W3207930223 @default.
- W4220839484 cites W4211147182 @default.
- W4220839484 cites W4225880044 @default.
- W4220839484 cites W4226081403 @default.
- W4220839484 cites W2405170650 @default.
- W4220839484 doi "https://doi.org/10.3389/fped.2022.836230" @default.
- W4220839484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35359899" @default.
- W4220839484 hasPublicationYear "2022" @default.
- W4220839484 type Work @default.
- W4220839484 citedByCount "5" @default.
- W4220839484 countsByYear W42208394842022 @default.
- W4220839484 countsByYear W42208394842023 @default.
- W4220839484 crossrefType "journal-article" @default.
- W4220839484 hasAuthorship W4220839484A5000208648 @default.
- W4220839484 hasAuthorship W4220839484A5002282668 @default.
- W4220839484 hasAuthorship W4220839484A5006381517 @default.
- W4220839484 hasAuthorship W4220839484A5019494622 @default.
- W4220839484 hasAuthorship W4220839484A5021655364 @default.
- W4220839484 hasAuthorship W4220839484A5022827045 @default.
- W4220839484 hasAuthorship W4220839484A5032323430 @default.
- W4220839484 hasAuthorship W4220839484A5034848722 @default.
- W4220839484 hasAuthorship W4220839484A5045906857 @default.
- W4220839484 hasAuthorship W4220839484A5051825864 @default.
- W4220839484 hasAuthorship W4220839484A5057281435 @default.
- W4220839484 hasAuthorship W4220839484A5064431563 @default.
- W4220839484 hasAuthorship W4220839484A5064732539 @default.
- W4220839484 hasAuthorship W4220839484A5071719710 @default.
- W4220839484 hasAuthorship W4220839484A5077267547 @default.
- W4220839484 hasAuthorship W4220839484A5078378771 @default.
- W4220839484 hasAuthorship W4220839484A5078789108 @default.
- W4220839484 hasAuthorship W4220839484A5085425383 @default.